Sutro Biopharma, Inc. $STRO Shares Purchased by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC grew its holdings in shares of Sutro Biopharma, Inc. (NASDAQ:STRO) by 42.9% in the first quarter, according to its most recent filing with the SEC. The firm owned 1,069,519 shares of the company’s stock after acquiring an additional 321,137 shares during the quarter. Sutro Biopharma comprises approximately 1.4% of Affinity Asset Advisors LLC’s holdings, making the stock its 22nd largest position. Affinity Asset Advisors LLC owned approximately 0.06% of Sutro Biopharma worth $26,642,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. State of Tennessee Department of Treasury acquired a new position in shares of Sutro Biopharma during the fourth quarter valued at $86,000. Sigma Planning Corp acquired a new position in Sutro Biopharma during the 1st quarter valued at about $312,000. Jane Street Group LLC bought a new stake in shares of Sutro Biopharma during the 4th quarter worth about $265,000. Bridgeway Capital Management LLC raised its position in shares of Sutro Biopharma by 232.6% during the 3rd quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock worth $37,000 after buying an additional 30,000 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in shares of Sutro Biopharma by 51.3% in the 3rd quarter. Bank of America Corp DE now owns 119,434 shares of the company’s stock worth $104,000 after acquiring an additional 40,488 shares during the period. 96.99% of the stock is owned by institutional investors and hedge funds.

Sutro Biopharma Stock Performance

Shares of NASDAQ:STRO opened at $22.88 on Friday. The company has a market capitalization of $379.12 million, a PE ratio of -2.07 and a beta of 1.51. The stock has a fifty day moving average of $28.27 and a 200-day moving average of $24.81. Sutro Biopharma, Inc. has a one year low of $7.15 and a one year high of $43.85.

Sutro Biopharma (NASDAQ:STRO) last issued its earnings results on Thursday, May 14th. The company reported ($2.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.74) by ($0.20). The company had revenue of $14.52 million during the quarter, compared to analyst estimates of $8.89 million. As a group, research analysts forecast that Sutro Biopharma, Inc. will post -9 EPS for the current fiscal year.

Wall Street Analyst Weigh In

STRO has been the subject of several recent analyst reports. Mizuho set a $50.00 price objective on shares of Sutro Biopharma and gave the company an “outperform” rating in a report on Thursday, April 30th. Citizens Jmp upped their target price on Sutro Biopharma from $35.00 to $41.00 and gave the stock a “market outperform” rating in a research report on Thursday, April 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sutro Biopharma in a research note on Friday, May 8th. Lifesci Capital upgraded Sutro Biopharma to a “strong-buy” rating in a research report on Friday, May 1st. Finally, Barclays initiated coverage on Sutro Biopharma in a research note on Thursday, May 28th. They issued an “overweight” rating and a $56.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $52.44.

Sutro Biopharma Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.